Ovarian volume partially explains associations of phthalate biomarkers with anti-Müllerian hormone and estradiol in midlife women.
Anti-Müllerian hormone
Estradiol
Midlife
Ovarian volume
Phthalates
Journal
Environment international
ISSN: 1873-6750
Titre abrégé: Environ Int
Pays: Netherlands
ID NLM: 7807270
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
received:
01
11
2022
revised:
23
12
2022
accepted:
20
01
2023
pubmed:
2
2
2023
medline:
25
2
2023
entrez:
1
2
2023
Statut:
ppublish
Résumé
Women are ubiquitously exposed to endocrine disruptors, including phthalates. Ovarian follicles undergoing folliculogenesis (indirectly measured by ovarian volume) produce anti-Müllerian hormone (AMH) and estradiol (E2). We evaluated associations of phthalates with ovarian volume to assess whether this explained prior positive associations of phthalates with AMH and E2. Women ages 45-54 years (n = 614) had transvaginal ultrasounds of right/left ovaries to calculate mean ovarian volume. Women provided up-to-four urine and blood samples for quantifying AMH (first serum sample), E2 (all serum samples), and nine phthalate metabolites (from pooled urine, representing six parent phthalates). Multivariable linear or logistic regression models (for individual phthalate biomarkers), as well as weighted quantile sum (WQS) regression (for mixture analyses) evaluated associations of phthalate biomarkers with ovarian volume. Using cross-sectional mediation analysis, we assessed whether associations of phthalates with ovarian volume partially explained those of phthalates with AMH or E2. Most women were non-Hispanic White (68%) and pre-menopausal (67%) with higher urinary phthalate metabolite concentrations than U.S. women. In single-pollutant models, 10% increases in mono(3-carboxypropyl) phthalate (MCPP) and monobenzyl phthalate (MBzP) were associated with 0.44% (95% CI: -0.02%, 0.91%) and 0.62% (95% CI: 0.02%, 1.23%) larger ovarian volumes, respectively. As a cumulative mixture, 10% increases in the phthalate mixture were associated with 2.89% larger ovarian volume (95%CI: 0.27, 5.59) with MCPP (35%) and MBzP (41%) identified as major contributors. Higher ovarian volume due to a 10% increase in MBzP (indirect effect OR: 1.004; 95% CI: 1.00, 1.01) explained 16% of the positive association between MBzP and higher AMH, whereas higher ovarian volume due to a 10% increase in MCPP (indirect effect %Δ: 0.11; 95% CI: -0.01, 0.22) explained 23% of the positive association between MCPP and E2. In this cross-sectional study, phthalates were associated with increased ovarian volume, with implications for midlife hormone production.
Sections du résumé
BACKGROUND/OBJECTIVES
Women are ubiquitously exposed to endocrine disruptors, including phthalates. Ovarian follicles undergoing folliculogenesis (indirectly measured by ovarian volume) produce anti-Müllerian hormone (AMH) and estradiol (E2). We evaluated associations of phthalates with ovarian volume to assess whether this explained prior positive associations of phthalates with AMH and E2.
METHODS
Women ages 45-54 years (n = 614) had transvaginal ultrasounds of right/left ovaries to calculate mean ovarian volume. Women provided up-to-four urine and blood samples for quantifying AMH (first serum sample), E2 (all serum samples), and nine phthalate metabolites (from pooled urine, representing six parent phthalates). Multivariable linear or logistic regression models (for individual phthalate biomarkers), as well as weighted quantile sum (WQS) regression (for mixture analyses) evaluated associations of phthalate biomarkers with ovarian volume. Using cross-sectional mediation analysis, we assessed whether associations of phthalates with ovarian volume partially explained those of phthalates with AMH or E2.
RESULTS
Most women were non-Hispanic White (68%) and pre-menopausal (67%) with higher urinary phthalate metabolite concentrations than U.S. women. In single-pollutant models, 10% increases in mono(3-carboxypropyl) phthalate (MCPP) and monobenzyl phthalate (MBzP) were associated with 0.44% (95% CI: -0.02%, 0.91%) and 0.62% (95% CI: 0.02%, 1.23%) larger ovarian volumes, respectively. As a cumulative mixture, 10% increases in the phthalate mixture were associated with 2.89% larger ovarian volume (95%CI: 0.27, 5.59) with MCPP (35%) and MBzP (41%) identified as major contributors. Higher ovarian volume due to a 10% increase in MBzP (indirect effect OR: 1.004; 95% CI: 1.00, 1.01) explained 16% of the positive association between MBzP and higher AMH, whereas higher ovarian volume due to a 10% increase in MCPP (indirect effect %Δ: 0.11; 95% CI: -0.01, 0.22) explained 23% of the positive association between MCPP and E2.
CONCLUSION
In this cross-sectional study, phthalates were associated with increased ovarian volume, with implications for midlife hormone production.
Identifiants
pubmed: 36724714
pii: S0160-4120(23)00044-2
doi: 10.1016/j.envint.2023.107771
pmc: PMC10012419
mid: NIHMS1876060
pii:
doi:
Substances chimiques
phthalic acid
6O7F7IX66E
Anti-Mullerian Hormone
80497-65-0
Estradiol
4TI98Z838E
Environmental Pollutants
0
Phthalic Acids
0
Biomarkers
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
107771Subventions
Organisme : NICHD NIH HHS
ID : K12 HD050121
Pays : United States
Organisme : NIEHS NIH HHS
ID : R01 ES026956
Pays : United States
Organisme : NIEHS NIH HHS
ID : T32 ES007255
Pays : United States
Informations de copyright
Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Hum Reprod. 2000 Sep;15(9):1921-6
pubmed: 10966987
Menopause. 2003 May-Jun;10(3):209-13
pubmed: 12792291
Toxics. 2022 May 16;10(5):
pubmed: 35622664
Int J Gynaecol Obstet. 2013 Dec;123 Suppl 2:S9-17
pubmed: 24139473
Best Pract Res Clin Endocrinol Metab. 2021 Sep;35(5):101552
pubmed: 34238683
J Clin Endocrinol Metab. 2011 Mar;96(3):746-54
pubmed: 21159842
Endocrinology. 2017 Jun 1;158(6):1739-1754
pubmed: 28368545
Biol Reprod. 2015 May;92(5):120
pubmed: 25810477
Chemosphere. 2019 Jul;226:597-606
pubmed: 30954894
Menopause. 2001 May-Jun;8(3):175-80
pubmed: 11355039
Psychol Methods. 2013 Jun;18(2):137-50
pubmed: 23379553
Gynecol Oncol. 2000 Jun;77(3):410-2
pubmed: 10831351
Toxicol Sci. 2018 Jun 1;163(2):420-429
pubmed: 29471507
Environ Health Perspect. 2002 May;110(5):515-8
pubmed: 12003755
Int J Gynaecol Obstet. 2013 Dec;123 Suppl 2:S18-24
pubmed: 24119894
Environ Int. 2021 Nov;156:106633
pubmed: 34004451
Multivariate Behav Res. 2011 Sep 30;46(5):852-60
pubmed: 26736049
Sci Total Environ. 2021 May 15;769:144560
pubmed: 33493905
Toxics. 2021 Nov 11;9(11):
pubmed: 34822691
Gynecol Endocrinol. 2017 Apr;33(4):320-323
pubmed: 27910705
Fertil Steril. 2020 Dec;114(6):1151-1157
pubmed: 33280722
J Endocrinol. 2017 Jun;233(3):R109-R129
pubmed: 28356401
J Clin Endocrinol Metab. 2014 Nov;99(11):4346-52
pubmed: 25121464
Fertil Steril. 1995 Dec;64(6):1167-71
pubmed: 7589671
J Assist Reprod Genet. 2020 Jun;37(6):1267-1272
pubmed: 32215823
J Korean Med Sci. 2021 Jan 11;36(2):e1
pubmed: 33429469
Gynecol Endocrinol. 2012 Jun;28(6):432-5
pubmed: 22122694
Chemosphere. 2020 Mar;242:125206
pubmed: 31678849
J Womens Health (Larchmt). 2016 Apr;25(4):409-15
pubmed: 26667258
Int J Epidemiol. 2013 Oct;42(5):1511-9
pubmed: 24019424
Environ Res. 2020 Nov;190:110009
pubmed: 32777275
Hum Reprod. 1992 Nov;7(10):1342-6
pubmed: 1291557
J Reprod Med. 2002 Oct;47(10):835-9
pubmed: 12418067
Reprod Toxicol. 2003 Mar-Apr;17(2):163-70
pubmed: 12642148
Environ Res. 2022 Nov;214(Pt 3):114056
pubmed: 35952743
Reprod Toxicol. 2021 Dec;106:25-31
pubmed: 34597818
Psychol Methods. 2007 Mar;12(1):23-44
pubmed: 17402810
MethodsX. 2019 Nov 22;6:2855-2860
pubmed: 31871919
Environ Res. 2021 Mar;194:110598
pubmed: 33307086
Multivariate Behav Res. 2018 May-Jun;53(3):375-402
pubmed: 29624079
Int J Hyg Environ Health. 2017 Mar;220(2 Pt A):179-188
pubmed: 27923611
Toxicol Appl Pharmacol. 2020 Feb 1;388:114875
pubmed: 31884101
Environ Int. 2021 Dec;157:106809
pubmed: 34375942
Epidemiology. 2016 Nov;27(6):879-88
pubmed: 27299194
Fertil Steril. 2019 Nov;112(5):939-946
pubmed: 31395310
Environ Health Perspect. 2004 Mar;112(3):331-8
pubmed: 14998749
Reprod Toxicol. 2018 Sep;80:60-67
pubmed: 29969652
J Am Coll Cardiol. 2018 Jan 2;71(1):69-84
pubmed: 29301630
Hum Reprod. 2004 Jul;19(7):1612-7
pubmed: 15205396
J Agric Biol Environ Stat. 2015 Mar;20(1):100-120
pubmed: 30505142
Gynecol Endocrinol. 2019 Apr;35(4):364-367
pubmed: 30638094
Climacteric. 2004 Sep;7(3):255-60
pubmed: 15669549
Hum Reprod. 2016 Jan;31(1):75-83
pubmed: 26573529
Obstet Gynecol. 1999 Jul;94(1):57-60
pubmed: 10389718
J Am Coll Cardiol. 2014 Jul 1;63(25 Pt B):2985-3023
pubmed: 24239920
Hum Reprod Update. 1999 May-Jun;5(3):256-66
pubmed: 10438110
PLoS One. 2015 Jan 28;10(1):e0116057
pubmed: 25629726
Curr Environ Health Rep. 2022 Mar;9(1):53-79
pubmed: 35103957
Environ Res. 2013 Oct;126:91-7
pubmed: 23890968
Obstet Gynecol Int. 2012;2012:305025
pubmed: 22496698
Acta Obstet Gynecol Scand. 1995 Mar;74(3):208-11
pubmed: 7900525
Toxicol Appl Pharmacol. 1994 Oct;128(2):216-23
pubmed: 7940536
Environ Health Perspect. 2015 Oct;123(10):965-70
pubmed: 25748701
Womens Midlife Health. 2017 Aug 17;3:4
pubmed: 30766705
Nat Rev Endocrinol. 2018 Apr;14(4):199-215
pubmed: 29393299
Menopause. 2012 Apr;19(4):387-95
pubmed: 22343510
J Hazard Mater. 2022 Aug 15;436:129213
pubmed: 35739735
Womens Health Rep (New Rochelle). 2022 Jun 13;3(1):573-581
pubmed: 35814604
Environ Sci Pollut Res Int. 2016 Jan;23(1):455-68
pubmed: 26310707
Am J Epidemiol. 2007 Nov 1;166(9):1096-104
pubmed: 17702973
Environ Health Perspect. 2009 Oct;117(10):1587-92
pubmed: 20019910
Environ Toxicol. 2022 Oct;37(10):2566-2578
pubmed: 35861251
Reprod Toxicol. 2015 Jan;51:47-56
pubmed: 25530038
Epidemiology. 1990 Jan;1(1):43-6
pubmed: 2081237
Sci Rep. 2018 Feb 22;8(1):3447
pubmed: 29472605
Recent Prog Horm Res. 2002;57:257-75
pubmed: 12017547
Environ Health Perspect. 2012 Mar;120(3):458-63
pubmed: 22113848
Environ Health Perspect. 2010 Jun;118(6):825-32
pubmed: 20185384
Adv Pharmacol. 2021;92:151-190
pubmed: 34452686
Front Endocrinol (Lausanne). 2015 Feb 02;6:8
pubmed: 25699018
J Clin Endocrinol Metab. 1976 Feb;42(2):247-53
pubmed: 177438
Neurotoxicology. 2021 Dec;87:167-173
pubmed: 34599995
Int J Environ Res Public Health. 2022 Feb 26;19(5):
pubmed: 35270433
Endocrinology. 2018 Feb 1;159(2):795-809
pubmed: 29228129
Multivariate Behav Res. 2013 May;48(3):301-39
pubmed: 26741846
Toxicol Sci. 2019 May 1;169(1):246-259
pubmed: 30768133
Eur J Endocrinol. 2003 Feb;148(2):227-32
pubmed: 12590642
Environ Int. 2018 Feb;111:23-31
pubmed: 29161633
J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Dec 1;860(1):106-12
pubmed: 17997365
Healthcare (Basel). 2021 May 18;9(5):
pubmed: 34069956
Curr Dev Nutr. 2019 Dec 05;4(1):nzz139
pubmed: 31893261